Advanced drug delivery systems of curcumin for cancer chemoprevention

Cancer Prevention Research

Volumn 4, Issue 8, 2011, Pages 1158-1171

  Bansal, Shyam S ^a   Goel, Mehak ^a   Aqil, Farrukh ^b   Vadhanam, Manicka V ^b   Gupta, Ramesh C ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA CAROTENE; CURCUMA LONGA EXTRACT; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; ELLAGIC ACID; GAMMA ORYZANOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; NANOPARTICLE; POLYMER; POLYPHENOL DERIVATIVE; RESVERATROL; SOLID LIPID NANOPARTICLE; SUPEROXIDE DISMUTASE;

ANTIANGIOGENIC ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; COLORECTAL CANCER; CRITICAL MICELLE CONCENTRATION; CURCUMA LONGA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG RELEASE; HUMAN; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; LIVER PROTECTION; METASTASIS INHIBITION; MICROEMULSION; NONHUMAN; PANCREAS CANCER; POLYMERIC IMPLANTABLE DEVICE; POLYMERIZATION; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TEA; ULTRAFLOW LIQUID CHROMATOGRAPHY;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; CURCUMIN; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; LACTIC ACID; LIPOSOMES; MICE; MICROSCOPY, ATOMIC FORCE; MODELS, CHEMICAL; NANOPARTICLES; NEOPLASMS; POLYGLYCOLIC ACID;

EID: 80051487233     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0006     Document Type: Review

References (105)

1. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21:525-30. (Pubitemid 30137938)
2. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2699-702.
3. Shureiqi I, Reddy P, Brenner DE. Chemoprevention: general perspective. Crit Rev Oncol Hematol 2000;33:157-67. (Pubitemid 30163069)
4. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigal-locatechin-3-gallate. Cancer Res 2009;69:1712-6.
5. Sonaje K, Italia JL, Sharma G, Bhardwaj V, Tikoo K, Kumar MN. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats. Pharm Res 2007;24:899-908. (Pubitemid 46675391)
6. Fang JY, Hung CF, Hwang TL, Huang YL. Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J Drug Target 2005;13:19-27.
7. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009;125:1-8.
8. Scalia S, Mezzena M. Incorporation of quercetin in lipid microparticles: effect on photo- and chemical-stability. J Pharm Biomed Anal 2009;49:90-4.
9. Shutava TG, Balkundi SS, Lvov YM. (-)-Epigallocatechin gallate/ gelatin layer-by-layer assembled films and microcapsules. J Colloid Interface Sci 2009;330:276-83.
10. Bansal SS, Vadhanam MV, Gupta RC. Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm Res 2011;28:1121-30.
11. Meyskens FL Jr, McLaren CE. Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst 2010;102:1815-7.
12. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009;30:85-94.
13. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008;76:1590-611.
14. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40-59.
15. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98. (Pubitemid 36361976)
16. Aggarwal BB. Apoptosis and nuclear factor-kappa B: a tale of association and dissociation. Biochem Pharmacol 2000;60:1033-9.
17. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 1997;77:772-82. (Pubitemid 27182979)
18. Brennan P, O'Neill LA. Inhibition of nuclear factor kappaB by direct modification in whole cells-mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem Pharmacol 1998;55:965-73. (Pubitemid 28167718)
19. Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 2006;8: E443-9. (Pubitemid 44096605)
20. Singh SV, Hu X, Srivastava SK, Singh M, Xia H, Orchard JL, et al. Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis 1998;19:1357-60. (Pubitemid 28409831)
21. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 2003;371: 887-95. (Pubitemid 36578887)
22. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004;1:85-96.
23. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999;27:486-94.
24. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353-6. (Pubitemid 28234275)
25. Ravindranath V, Chandrasekhara N. Metabolism of curcumin-studies with [3H]curcumin. Toxicology 1981;22:337-44.
26. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4: 807-18.
27. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res 2011;4:354-64.
28. Wahlang B, Pawar YB, Bansal AK. Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Eur J Pharm Biopharm 2011;77:275-82.
29. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11:105-11. (Pubitemid 34118319)
30. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology 1981;20:251-7. (Pubitemid 11117911)
31. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980;16:259-65. (Pubitemid 10056763)
32. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene- 3,5-dione) in the rat. Xenobiotica 1978;8:761-8. (Pubitemid 9119050)
33. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res A 2008;86:300-10. (Pubitemid 351969628)
34. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 2008;32:1119-23.
35. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010;79: 330-8.
36. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 2007; 5:3.
37. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9- fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009;37:223-30.
38. Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009;6:928-39.
39. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007;330:155-63. (Pubitemid 46097368)
40. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol 1978;43:86-92. (Pubitemid 9016316)
41. Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, et al. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 2001;7:1452-8. (Pubitemid 32708702)
42. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001;61:1058-64. (Pubitemid 32174425)
43. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008;28:110-3.
44. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14: 4491-9.
45. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21: 2895-900.
46. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004;90:1011-5. (Pubitemid 38499692)
47. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008;4:273-82.
48. Khan JA, Kainthan RK, Ganguli M, Kizhakkedathu JN, Singh Y, Maiti S. Water soluble nanoparticles from PEG-based cationic hyperbranched polymer and RNA that protect RNA from enzymatic degradation. Biomacromolecules 2006;7:1386-8. (Pubitemid 43811192)
49. Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CH, Alabi CA, et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT- 101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A 2009;106:11394-9.
50. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nano-particles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release 2007;119:197-206. (Pubitemid 46778760)
51. Grabovac V, Bernkop-Schnurch A. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine. Drug Dev Ind Pharm 2007;33:767-74. (Pubitemid 47123803)
52. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 2005;1:193-212. (Pubitemid 43963632)
53. Volkheimer G, Schulz FH, Lehmann H, Aurich I, Hubner R, Hubner M, et al. Primary portal transport of persorbed starch granules from the intestinal wall. Med Exp Int J Exp Med 1968;18:103-8.
54. Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 2001;50:107-42. (Pubitemid 32727279)
55. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998;95:4607-12. (Pubitemid 28207960)
56. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6.
57. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305. (Pubitemid 16076428)
58. Siflinger-Birnboim A, Del Vecchio PJ, Cooper JA, Blumenstock FA, Shepard JM, Malik AB. Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol 1987;132:111-7. (Pubitemid 17105330)
59. Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: physicochemical characterization and stability study. Eur J Pharm Sci 2009;37: 395-404.
60. Petri B, Bootz A, Khalansky A, Hekmatara T, Muller R, Uhl R, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant- coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release 2007;117:51-8. (Pubitemid 46164866)
61. Werle M, Takeuchi H, Bernkop-Schnurch A. Modified chitosans for oral drug delivery. J Pharm Sci 2009;98:1643-56.
62. Werle M, Hoffer M. Glutathione and thiolated chitosan inhibit multi-drug resistance P-glycoprotein activity in excised small intestine. J Control Release 2006;111:41-6. (Pubitemid 43289993)
63. Ai H, Jones SA, Lvov YM. Biomedical applications of electrostatic layer-by-layer nano-assembly of polymers, enzymes, and nanoparticles. Cell Biochem Biophys 2003;39:23-43. (Pubitemid 41282439)
64. Shutava TG, Balkundi SS, Vangala P, Steffan JJ, Bigelow RL, Cardelli JA, et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano 2009;3:1877-85.
65. Koppolu BP, Rahimi M, Nattama SP, Wadajkar A, Nguyen K. Development of multiple-layer polymeric particles for targeted and controlled drug delivery. Nanomedicine 2010;6:355-61.
66. Willis M, Forssen E. Ligand-targeted liposomes. Adv Drug Deliv Rev 1998;29:249-71. (Pubitemid 28090045)
67. Salmaso S, Bersani S, Semenzato A, Caliceti P. New cyclodextrin bioconjugates for active tumour targeting. J Drug Target 2007; 15:379-90. (Pubitemid 47073053)
68. Gasco MR. Lipid nanoparticles: perspectives and challenges. Adv Drug Deliv Rev 2007;59:377-8. (Pubitemid 47259229)
69. Siekmann B, Westesen K. Sub-micron sized parenteral carrier systems based on solid lipid. Pharmacol Lett 1992;1:123-6.
70. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77. (Pubitemid 30326695)
71. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97-109.
72. Marengo E, Cavalli R, Caputo O, Rodriguez L, Gasco MR. Scale-up of the preparation process of solid lipid nanospheres. Part I. Int J Pharm 2000;205:3-13.
73. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-96. (Pubitemid 32324113)
74. Sou K, Inenaga S, Takeoka S, Tsuchida E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm 2008;352:287-93.
75. Kristl J, Teskac K, Caddeo C, Abramovic Z, Sentjurc M. Improvements of cellular stress response on resveratrol in liposomes. Eur J Pharm Biopharm 2009;73:253-9.
76. Viriyaroj A, Ngawhirunpat T, Sukma M, Akkaramongkolporn P, Ruktanonchai U, Opanasopit P. Physicochemical properties and antioxidant activity of gamma-oryzanol-loaded liposome formulations for topical use. Pharm Dev Technol 2009;14:665-71.
77. Mitsopoulos P, Omri A, Alipour M, Vermeulen N, Smith MG, Suntres ZE. Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents. Int J Pharm 2008;363:106-11.
78. Kunwar A, Barik A, Pandey R, Priyadarsini KI. Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim Biophys Acta 2006; 1760:1513-20.
79. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31. (Pubitemid 41282806)
80. Chen C, Johnston TD, Jeon H, Gedaly R, McHugh PP, Burke TG, et al. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int J Pharm 2009;366:133-9.
81. Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 2008;14:6228-36.
82. Jung S, Otberg N, Thiede G, Richter H, Sterry W, Panzner S, et al. Innovative liposomes as a transfollicular drug delivery system: penetration into porcine hair follicles. J Invest Dermatol 2006;126: 1728-32. (Pubitemid 44086505)
83. Wattanakrai P, Suwanachote S, Kulkollakarn S, Rajatanavin N. The study of human skin irritation of a novel herbal skin care product and ingredients by human single closed patch testing. J Med Assoc Thai 2007;90:1116-22. (Pubitemid 47013734)
84. Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009;98:411-29.
85. Lee MH, Lin HY, Chen HC, Thomas JL. Ultrasound mediates the release of curcumin from microemulsions. Langmuir 2008;24:1707-13. (Pubitemid 351500922)
86. Santos P, Watkinson AC, Hadgraft J, Lane ME. Application of microemulsions in dermal and transdermal drug delivery. Skin Pharmacol Physiol 2008;21:246-59.
87. Teichmann A, Heuschkel S, Jacobi U, Presse G, Neubert RH, Sterry W, et al. Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur J Pharm Biopharm 2007;67:699-706. (Pubitemid 47576613)
88. Boriwanwattanarak P, Ingkaninan K, Khorana N, Viyoch J. Development of curcuminoids hydrogel patch using chitosan from various sources as controlled-release matrix. Int J Cosmet Sci 2008;30: 205-18. (Pubitemid 351623838)
89. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007;337:299-306. (Pubitemid 46756048)
90. Aziz HA, Peh KK, Tan YT. Solubility of core materials in aqueous polymeric solution effect on microencapsulation of curcumin. Drug Dev Ind Pharm 2007;33:1263-72. (Pubitemid 350208730)
91. Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L, Panyam J. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res 2010;70: 4443-52.
92. Domb AJ, Israel ZH, Elmalak O, Teomim D, Bentolila A. Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors. Pharm Res 1999;16:762-5. (Pubitemid 29227109)
93. Jain JP, Modi S, Domb AJ, Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release 2005;103:541-63. (Pubitemid 40476140)
94. Langer R. Drug delivery and targeting. Nature 1998;392:5-10. (Pubitemid 28215187)
95. Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998;40:1-12. (Pubitemid 29062900)
96. Saltzman WM, Fung LK. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 1997;26:209-30. (Pubitemid 27289535)
97. Weinberg BD, Blanco E, Gao J. Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci 2008;97:1681-702.
98. Gupta RC, Bansal SS, Aqil F, Cao P, Jeyabalan J, Russel GK, et al. A novel concept in delivering chemopreventive compounds [abstract]. In: Proceedings of the 100th Annual Meeting of American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR;2009.
99. Bansal SS, Jeyabalan J, Vadhanam MV, Gupta RC. Effect of sustained, low-dose curcumin on benzo[a]pyrene-induced tissue DNA adducts in rat model [abstract]. In: Proceedings of the 99th Annual Meeting of American Association for Cancer Research; 2008 April 12-16. San Diego, CA Philadelphia (PA): AACR; 2008.
100. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010;390:61-9.
101. Wu TH, Yen FL, Lin LT, Tsai TR, Lin CC, Cham TM. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 2008;346:160-8.
102. Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res 2006;12:3193-9.
103. Hentschel A, Gramdorf S, Muller RH, Kurz T. Beta-carotene-loaded nanostructured lipid carriers. J Food Sci 2008;73:N1-6.
104. Das S, Ng KY, Ho PC. Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaral-dehyde as the hardening agent for colonic-specific delivery of resveratrol: in vitro and in vivo evaluations. J Drug Target 2010;19:446-57.
105. Cao P, Vadhanam MV, Spencer WA, Cai J, Gupta RC. Sustained systemic delivery of green tea polyphenols by polymeric implants significantly diminishes benzo[a]pyrene-induced DNA adducts. Chem Res Toxicol 2011 May 31 [Epub ahead of print].